A prospective, multicenter, open-label, randomized controlled study to assess the effects of early intensive lipid-lowering initiated before endovascular treatment setting on (i) functional outcome in patients with acute ischemic stroke between preoperative intensive lipid-lowering therapy with PCSK9 inhibitor (PCSK9i) and guideline-recommended standard of care (SoC)(ii) safety in these patients.
Adults (age 18 years and older);
Imaging diagnosis of acute ischemic stroke with anterior circulation large vessel occlusion (including: internal carotid artery, middle cerebral artery M1 and M2, anterior cerebral artery A1 and A2);
Planned to undergo endovascular intervention within 24 hours of symptom onset (or last known well time) according to local guidelines;
Provision of informed consent by the patient or his/her legally authorized representative (or by an appropriate agent according to local requirements).
ASPECTS score ≤5 on cranial CT imaging;
Pre-existing functional impairment, with mRS score >2;
Patients who are allergic to PCSK9 inhibitors;
Patients who have received PCSK9 monoclonal antibody within 1 month prior to enrollment or PCSK9 siRNA therapy within 6 months prior to enrollment;